Cytori Therapeutics to Present Preliminary Safety and Efficacy Preclinical Data at the 2016 American Burn Association Meeting
SAN DIEGO–(BUSINESS WIRE)–Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that data from preclinical studies showing potential for Cytori’s DCCT-10 cell therapy product in the treatment of hypertrophic scarring (HTS), a common consequence of burn injury, will be presented at the Annual Meeting of the American Burn Association (ABA) in Las Vegas on May 5, 2016. This research is a continuation of Cytori’s ongoing …
SAN DIEGO–(BUSINESS WIRE)–Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that data from preclinical studies showing potential for Cytori’s DCCT-10 cell therapy product in the treatment of hypertrophic scarring (HTS), a common consequence of burn injury, will be presented at the Annual Meeting of the American Burn Association (ABA) in Las Vegas on May 5, 2016.
This research is a continuation of Cytori’s ongoing contract with the Biomedical Advanced Research and Development Authority (BARDA). As part of this work Cytori has developed a reproducible model possessing several of the characteristics of the HTS that occurs in humans following burn injury. In one study this model was applied to assess the ability of DCCT-10 treatment delivered immediately following initial burn surgery to impact the development of HTS. In a second study the same model was applied to assess use of DCCT-10 delivered six months after deep partial thickness injury in which a hypertrophic scar had already formed. The Cytori presentation will include early data indicating a potential beneficial effect of DCCT-10 in both processes.This research is an extension of earlier work that reported data suggesting that use of DCCT-10 was associated with improvement in several parameters associated with healing following thermal burn injury.
Hypertrophic scars are areas of hard, raised, red or purple scar tissue often form at the site of burn injury. They are frequently hypersensitive and itchy. When present at or near a joint they can form
contractures that reduce range of motion. In the absence of adequate non-surgical treatment options, the most effective approach has been to attempt to prevent or limit the formation of these scars by
post-surgical use of pressure garments, steroid injections, and silicone sheets. Surgical intervention is often used to release contracture.
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefit across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products.
For more information: visit www.cytori.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts are forward looking statements. Such statements are
subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include pre-clinical and clinical associated with the BARDA wound trial
(including risks in the collection and results of clinical data), and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission Filings, included in our
annual and quarterly reports.
There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no
responsibility to update or revise any forward- looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities.